92 related articles for article (PubMed ID: 18766005)
1. Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Nishimura R; Tominaga T; Kimura M; Yanagita Y; Tamaki N; Asaishi K; Okamoto Y; Okuyama N; Takeuchi H; Inaba M; Doi T
Anticancer Drugs; 2008 Oct; 19(9):911-5. PubMed ID: 18766005
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
Okamoto Y; Tominaga T; Okuyama N; Sawada T; Kou Y
Gan To Kagaku Ryoho; 2003 May; 30(5):661-7. PubMed ID: 12795098
[TBL] [Abstract][Full Text] [Related]
3. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Takiuchi H; Goto M; Imamura H; Furukawa H; Imano M; Imamoto H; Kimura Y; Ishida H; Fujitani K; Narahara H; Shimokawa T
Jpn J Clin Oncol; 2008 Mar; 38(3):176-81. PubMed ID: 18281707
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer.
Moriwaki T; Hyodo I; Nishina T; Hirao K; Tsuzuki T; Hidaka S; Kajiwara T; Endo S; Nasu J; Hirasaki S; Masumoto T; Kurita A
Cancer Chemother Pharmacol; 2005 Aug; 56(2):138-44. PubMed ID: 15827767
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval.
Nishimura R; Tominaga T; Mitsuyama S; Aoyama H; Asaga T; Ohno S; Okuyama N; Kimura M; Iwase H; Kanda K; Koga T; Shiba E; Ikeda T
Anticancer Res; 2004; 24(3b):2085-91. PubMed ID: 15274405
[TBL] [Abstract][Full Text] [Related]
6. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer.
Takeyoshi I; Makita F; Tanahashi Y; Iwazaki S; Ogawa T; Tomizawa N; Nakamura S; Ishikawa H; Ohya T; Kakinuma S; Nakagami K; Sato Y; Koyano T; Roppongi T; Izumi M; Kobayashi J; Kawate S; Sunose Y; Kobayashi M; Yamada T; Sakamoto I
Anticancer Res; 2011 Jan; 31(1):287-91. PubMed ID: 21273612
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
10. [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
Mizutani S; Oyama T; Hatanaka N; Uchikoshi F; Yoshidome K; Tori M; Ueshima S; Okuma K; Hiraoka K; Yamagami Y; Takahashi H; Sueyoshi K; Taira M; Nakahara M; Nakao K
Gan To Kagaku Ryoho; 2006 Mar; 33(3):327-31. PubMed ID: 16531712
[TBL] [Abstract][Full Text] [Related]
11. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
14. A combination phase I study of weekly paclitaxel and doxifluridine in advanced gastric cancer patients.
Takeyoshi I; Makita F; Tanahashi Y; Yokomori T; Iwazaki S; Kawashima Y; Iwanami K; Yamada T; Kawate S; Hamada K; Sunose Y; Yoshida M; Horiguchi J; Iesato H; Kobayashi M; Morishita Y
Anticancer Res; 2005; 25(2B):1291-6. PubMed ID: 15865080
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
19. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]